<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605826</url>
  </required_header>
  <id_info>
    <org_study_id>33DA0404</org_study_id>
    <nct_id>NCT00605826</nct_id>
  </id_info>
  <brief_title>A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence</brief_title>
  <official_title>A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oceana Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used&#xD;
      as an injectable bulking agent in the treatment of fecal incontinence. The study includes a&#xD;
      6-month blinded sham-controlled phase, followed by an open-label phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be given up to 2 treatments of NASHA/Dx or sham and followed for 6 months from&#xD;
      last treatment (ie, one retreatment is permitted at 1 month after the first injection) in the&#xD;
      blinded phase of the study. At Month 6, the open phase of the study will begin and subjects&#xD;
      on sham will be offered open-label treatment with NASHA/Dx.&#xD;
&#xD;
      Subjects who receive NASHA/Dx at the start of the blinded phase will be followed for up to 36&#xD;
      months from last treatment in the blinded phase. Subjects who receive sham at the start of&#xD;
      the blinded phase and then receive open-label NASHA/Dx at Month 6 (start of the open phase)&#xD;
      will be followed for another 24 months (equivalent to approximately 30 months from&#xD;
      randomization) from last treatment in the open phase of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2006</start_date>
  <completion_date type="Actual">November 23, 2009</completion_date>
  <primary_completion_date type="Actual">November 23, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Responder50.</measure>
    <time_frame>6 months after last blinded treatment</time_frame>
    <description>Percentage of participants who achieve ≥ 50% reduction in the number of fecal incontinence episodes compared to baseline (Responder50).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Responder25.</measure>
    <time_frame>12 months after last treatment</time_frame>
    <description>Response to treatment at 12 months was defined as a ≥ 25 % reduction in the number of fecal incontinence episodes compared to baseline (Responder25).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Fecal Incontinence Episodes</measure>
    <time_frame>up to 6 months after last treatment</time_frame>
    <description>The number of incontinence episodes collected from a participant incontinence diary spanning a period of 14 days prior to each of the study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence Free Days</measure>
    <time_frame>up to 6 months after last treatment</time_frame>
    <description>The number of days with no fecal incontinence episodes (incontinence free days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fecal Incontinence Quality of Life Scale (FIQL).</measure>
    <time_frame>up to 6 months after last treatment</time_frame>
    <description>The disease-specific Fecal Incontinence Quality of Life (FIQL) questionnaire is designed to capture the impact of treatment on quality of life for participants suffering from fecal incontinence as it pertains to 4 domains: Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The more the subject is affected by fecal incontinence the lower the value. Hence, a positive change from baseline indicates improvement. Scores range from 1 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleveland Clinic Florida Incontinence Score (CCFIS).</measure>
    <time_frame>up to 6 months after last treatment</time_frame>
    <description>Cleveland Clinic Florida Incontinence Score (CCFIS) score was based on a participant interview using standardized questions regarding incidence and type of incontinence (solid, liquid or gas), pad usage and lifestyle alterations during the past month. The score ranged from 0 (perfect) to 20 (complete incontinence)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Blinded injection of NASHA/Dx gel at randomization.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded sham inject. at randomization</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.&#xD;
Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.&#xD;
Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NASHA/Dx (Solesta) Gel</intervention_name>
    <description>Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.</description>
    <arm_group_label>Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.</arm_group_label>
    <arm_group_label>Blinded injection of NASHA/Dx gel at randomization.</arm_group_label>
    <other_name>Solesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Injection</intervention_name>
    <description>Sham injection at the start of the blinded phase.</description>
    <arm_group_label>Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.</arm_group_label>
    <arm_group_label>Blinded sham inject. at randomization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years of age, male or female.&#xD;
&#xD;
          -  Screening fecal incontinence severity score (CCFIS).&#xD;
&#xD;
          -  Fecal incontinence episodes over a 14-day period.&#xD;
&#xD;
          -  Failed conservative treatment for fecal incontinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complete external sphincter disruption.&#xD;
&#xD;
          -  Significant anorectal disease.&#xD;
&#xD;
          -  Anorectal surgery within the last 12 months prior to the study.&#xD;
&#xD;
          -  Active Inflammatory Bowel Disease (IBD).&#xD;
&#xD;
          -  Immunodeficiency or receiving immunosuppressive therapy.&#xD;
&#xD;
          -  Malignancies in remission for less than 2 years prior to the study.&#xD;
&#xD;
          -  Bleeding disorders or receiving anticoagulant therapy.&#xD;
&#xD;
          -  Chemotherapy within the last 12 months prior to the study.&#xD;
&#xD;
          -  Prior Pelvic radiotherapy.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding, or women of childbearing potential not&#xD;
             practicing adequate contraception or planning to stop such contraception within the&#xD;
             first year of the study.&#xD;
&#xD;
          -  Women within one year post partum.&#xD;
&#xD;
          -  Participation in any other clinical study within 3 month prior to the study.&#xD;
&#xD;
          -  Hypersensitivity to hyaluronic acid containing products.&#xD;
&#xD;
          -  Other severe conditions or in other ways unsuitable to participate according to&#xD;
             investigator judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco, Center for Pelvic Physiology, Dept. of Surgery</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine, Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic, Department of Colon &amp; Rectal Surgery</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colon &amp; Rectal Surgery Associates</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's/Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorectal Surgical Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Research/Center for Colon Rectal Disease</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Klinik Mit Poliklinik, FAU Erlangen-Nurnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>910 54</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgmottagningen Universitetssjukhuset MAS</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgmottagningen, Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirurgkliniken, Uppsala Akademiska Sjukhus</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital, Department of Academic Surgery</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <disposition_first_submitted>November 26, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 26, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 2, 2019</disposition_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NashaDx/Fecal</title>
          <description>NashaDx/Fecal - 4 syringes each containing 1 mL of product</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Sham - 4 empty syringes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NashaDx/Fecal</title>
          <description>NashaDx/Fecal - 4 syringes each containing 1 mL of product</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Sham - 4 empty syringes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" lower_limit="32.8" upper_limit="76.0"/>
                    <measurement group_id="B2" value="59.2" lower_limit="29.4" upper_limit="75.9"/>
                    <measurement group_id="B3" value="60.1" lower_limit="29.4" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Responder50.</title>
        <description>Percentage of participants who achieve ≥ 50% reduction in the number of fecal incontinence episodes compared to baseline (Responder50).</description>
        <time_frame>6 months after last blinded treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NashaDx/Fecal</title>
            <description>NashaDx/Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham - 4 empty syringes</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Responder50.</title>
          <description>Percentage of participants who achieve ≥ 50% reduction in the number of fecal incontinence episodes compared to baseline (Responder50).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Responder25.</title>
        <description>Response to treatment at 12 months was defined as a ≥ 25 % reduction in the number of fecal incontinence episodes compared to baseline (Responder25).</description>
        <time_frame>12 months after last treatment</time_frame>
        <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
        <group_list>
          <group group_id="O1">
            <title>NASHA/Dx Fecal</title>
            <description>NASHA/Dx Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Responder25.</title>
          <description>Response to treatment at 12 months was defined as a ≥ 25 % reduction in the number of fecal incontinence episodes compared to baseline (Responder25).</description>
          <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fecal Incontinence Episodes</title>
        <description>The number of incontinence episodes collected from a participant incontinence diary spanning a period of 14 days prior to each of the study visits.</description>
        <time_frame>up to 6 months after last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NashaDx/Fecal</title>
            <description>NashaDx/Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham - 4 empty syringes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fecal Incontinence Episodes</title>
          <description>The number of incontinence episodes collected from a participant incontinence diary spanning a period of 14 days prior to each of the study visits.</description>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.28" spread="2.15"/>
                    <measurement group_id="O2" value="18.53" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence Free Days</title>
        <description>The number of days with no fecal incontinence episodes (incontinence free days).</description>
        <time_frame>up to 6 months after last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NashaDx/Fecal</title>
            <description>NashaDx/Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham - 4 empty syringes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence Free Days</title>
          <description>The number of days with no fecal incontinence episodes (incontinence free days).</description>
          <units>incontinence free days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="6.68" upper_limit="8.52"/>
                    <measurement group_id="O2" value="6.48" lower_limit="5.41" upper_limit="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fecal Incontinence Quality of Life Scale (FIQL).</title>
        <description>The disease-specific Fecal Incontinence Quality of Life (FIQL) questionnaire is designed to capture the impact of treatment on quality of life for participants suffering from fecal incontinence as it pertains to 4 domains: Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The more the subject is affected by fecal incontinence the lower the value. Hence, a positive change from baseline indicates improvement. Scores range from 1 to 4.</description>
        <time_frame>up to 6 months after last treatment</time_frame>
        <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
        <group_list>
          <group group_id="O1">
            <title>NASHA/Dx Fecal</title>
            <description>NASHA/Dx Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fecal Incontinence Quality of Life Scale (FIQL).</title>
          <description>The disease-specific Fecal Incontinence Quality of Life (FIQL) questionnaire is designed to capture the impact of treatment on quality of life for participants suffering from fecal incontinence as it pertains to 4 domains: Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The more the subject is affected by fecal incontinence the lower the value. Hence, a positive change from baseline indicates improvement. Scores range from 1 to 4.</description>
          <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lifestyle domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping/Behavior domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression/Self perception domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embarrassment domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cleveland Clinic Florida Incontinence Score (CCFIS).</title>
        <description>Cleveland Clinic Florida Incontinence Score (CCFIS) score was based on a participant interview using standardized questions regarding incidence and type of incontinence (solid, liquid or gas), pad usage and lifestyle alterations during the past month. The score ranged from 0 (perfect) to 20 (complete incontinence)</description>
        <time_frame>up to 6 months after last treatment</time_frame>
        <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
        <group_list>
          <group group_id="O1">
            <title>NASHA/Dx Fecal</title>
            <description>NASHA/Dx Fecal - 4 syringes each containing 1 mL of product</description>
          </group>
        </group_list>
        <measure>
          <title>Cleveland Clinic Florida Incontinence Score (CCFIS).</title>
          <description>Cleveland Clinic Florida Incontinence Score (CCFIS) score was based on a participant interview using standardized questions regarding incidence and type of incontinence (solid, liquid or gas), pad usage and lifestyle alterations during the past month. The score ranged from 0 (perfect) to 20 (complete incontinence)</description>
          <population>This outcome measure was only analyzed for the NASHA/Dx group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <desc>Adverse events were assessed in all treated subjects and not by treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall</title>
          <description>Adverse events were assessed overall and not by randomized treatment group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>E. coli bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Multiple endocrine adenomatosis Type II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial senosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

